Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 3, 2010, Pages 286-291

  Carvas, Marcelo ^a   Nascimento, Bruno C G ^a   Acar, Mariana ^a   Nearing, Bruce D ^b   Belardinelli, Luiz ^c   Verrier, Richard L ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Gilead Palo Alto Incorporated   (United States)

Author keywords

Atrial electrical properties; Atrial fibrillation; Ranolazine; Vagal stimulation; Ventricular electrical properties; Ventricular fibrillation

Indexed keywords

RANOLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL PIG; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT ATRIUM; HEART RIGHT VENTRICLE; HEART VENTRICLE FIBRILLATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; TIME;

ACETANILIDES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS; MALE; PIPERAZINES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SWINE; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 77949596392     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d26416     Document Type: Article

References (38)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
2. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910. (Pubitemid 39136212)
3. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457.
4. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranzolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation. 2007;116:1647-1652.
5. Lew MJ, Ludbrook J, Pavia JM, et al. Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially. J Pharmacol Methods. 1987;17:137-148.
6. Darsinos JT, Samouilidou EC, Krumholz B, et al. Distribution of lidocaine and digoxin in heart tissues and aorta following intrapericardial administration. Int J Clin Pharmacol Ther Toxicol. 1993;31:611-615.
7. Ayers GM, Rho TH, Ben-David J, et al. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol. 1996; 7:713-721.
8. Fei L, Baron AD, Henry DP, et al. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation. 1997;96:4044-4049.
9. Waxman S, Moreno R, Rowe KA, et al. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol. 1999;33:2073-2077.
10. Moreno R, Waxman S, Rowe K, et al. Intrapericardial beta-adrenergic blockade with esmolol exerts a potent antitachycardic effect without depressing contractility. J Cardiovasc Pharmacol. 2000;36:722-727.
11. Baek SH, Hrabie JA, Keefer LK, et al. Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation. 2002; 105:2779-2784.
12. Gleason JD, Nguyen KP, Kissinger KV, et al. Myocardial drug distribution pattern following intrapericardial delivery: an MRI analysis. J Cardiovasc Magn Reson. 2002;4:311-316.
13. Hermans JJ, Van Essen H, Struijker-Boudier HA, et al. Pharmacokinetic advantage of intrapericardially applied substances in the rat. J Pharmacol Exp Ther. 2002;301:672-678.
14. Kumar K, Nguyen K, Waxman S, et al. Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart. J Am Coll Cardiol. 2003;41:1831-1837.
15. Van Brakel TJ, Hermans JJ, Janssen BJ, et al. Intrapericardial delivery enhances cardiac effects of sotalol and atenolol. J Cardiovasc Pharmacol. 2004;44:50-56.
16. Takada M, Dohi S, Akamatsu S, et al. Effects of pericardial lidocaine on hemodynamic parameters and responses in dogs anesthetized with midazolam and fentanyl. J Cardiothorac Vasc Anesth. 2007;21:393-399.
17. Xiao YF, Sigg DC, Ujhelyi MR, et al. Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias. Am J Physiol Heart Circ Physiol. 2008;294:H2212-H2218.
18. Van Brakel TJ, Hermans JJ, Accord RE, et al. Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. J Cardiovasc Electrophysiol. 2009;20:207-215.
19. Bolderman RW, Hermans JJR, Rademakers LMF, et al. Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects. J Cardiovasc Pharmacol. 2009;54:355-363.
20. Verrier RL, Waxman S, Lovett EG, et al. Transatrial access to the normal pericardial space: a novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation. 1998;98:2331-2333.
21. Maisch B, Ristic AD, Rupp H, et al. Pericardial access using the PERducer and flexible percutaneous pericardioscopy. Am J Cardiol. 2001;88:1323-1326.
22. D'Avila A, Scannavaca M, Sosa E, et al. Pericardial anatomy for the interventional electrophysiologist. J Cardiovasc Electrophysiol. 2003;14: 422-430.
23. Sicouri S, Glass A, Belardinelli L, et al. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5:1019-1026.
24. Moore EN, Spear JF. Ventricular fibrillation threshold: its physiological and pharmacological importance. Arch Intern Med. 1975:135:446-453.
25. Matta RJ, Verrier RL, Lown B. Repetitive extrasystole as an index of vulnerability to ventricular fibrillation. Am J Physiol. 1976;230:1469-1473.
26. Kowey PR, Verrier RL, Lown B. The repetitive extrasystole as an index of vulnerability to ventricular fibrillation during myocardial ischemia in the canine heart. Am Heart J. 1983;106:1321-1325.
27. Kumar K, Nearing BD, Bartoli CR, et al. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 2008;19:1073-1079.
28. Zhang Y, Ilsar I, Sabbah HN, et al. Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm. 2009;6: 244-250.
29. Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231-1237.
30. Scirica BM, Morrow DA, Karwatowska-Prokopczuk E, et al, TIMI Study Group. Ventricular arrhythmias following non-ST segment elevation ACS and the relationship with sudden cardiac death in the MERLIN-TIMI 36 Trial [Abstract]. J Am Coll Cardiol. 2009;53(Suppl 1):A121.
31. Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/ITo block. Am J Physiol Heart Circ Physiol. 2004;286:H2393-H2400.
32. Kumar K, Nearing BD, Carvas M, et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol. 2009;20: 796-802.
33. Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175-181.
34. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008; 372:1335-1341.
35. Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J Cardiovasc Pharmacol Ther. 2008;13:226-232.
36. Bartoli CR, Akiyama I, Godleski JJ, et al. Long-term pericardial catheterization is associated with minimum foreign-body response. Catheter Cardiovasc Interv. 2007;70:221-227.
37. Sosa E, Scanavacca M, D'Avila A, et al. Nonsurgical transthoracic epicardial approach in patients with ventricular tachycardia and previous cardiac surgery. J Interv Card Electrophysiol. 2004;10:281-288.
38. Corley SD, Epstein AE, DiMarco JP, et al, for the AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Circulation. 2004:109:1509-1513.